Nanoscope Therapeutics

Focus: Nanoscope Therapeutics is a Dallas-based gene therapy biotech focused on AAV-delivered opsin treatments for inherited retinal diseases. The company is pre-revenue and early-stage, founded in 2021.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Nanoscope Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Nanoscope Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Gene Therapy product:vMCO-I

Retinitis Pigmentosa

N/A

Clinical Trials (1)

NCT05921162A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection

N/A

Help build intelligence for Nanoscope Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in an emerging gene therapy company with a novel AAV-opsin platform targeting large, underserved retinal disease markets
Active pipeline with multiple Phase 1/2 and Phase 2 programs across Retinitis Pigmentosa and Stargardt Disease, offering direct visibility to clinical catalysts
Focused therapeutic area (ophthalmology gene therapy) allows deep specialization and meaningful scientific contribution in a high-impact space

Watch Out For

Company is pre-revenue with minimal disclosed funding data; financial runway and long-term stability are unconfirmed risks
Only 1 active job posting signals limited near-term hiring or possible resource constraints; career growth velocity may be constrained in a small organization

Generated by Claude from Nanoscope Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Gene Therapy Product-MCO-010

Stargardt Disease

N/A

Clinical Trials (1)

NCT06048185Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study

N/A

Observational

Macular Degeneration

N/A

Clinical Trials (1)

NCT06805474A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT

N/A